NCT05637970 is a NA clinical trial of Perclose in Arterial Occlusion, sponsored by University of California, Los Angeles.

Who is sponsoring NCT05637970?

NCT05637970 is sponsored by University of California, Los Angeles.

What drugs are being tested in NCT05637970?

Interventions in NCT05637970: Perclose, Statseal.

What condition does NCT05637970 study?

NCT05637970 studies Arterial Occlusion, Cardiovascular Diseases, Hematoma.

Is NCT05637970 still recruiting?

NCT05637970 is currently completed. Last updated 19 February 2025.

Are results published for NCT05637970?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-02-19 · How we verify

NCT05637970

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparing Perclose to Statseal With Perclose in Transcatheter Aortic Valve Replacement Arteriotomy Closure

Completed NA Results posted Last updated 19 February 2025

What this trial tests

NA trial testing Perclose in Arterial Occlusion in 50 participants. Completed in 25 July 2023.

Timeline

12 January 2023

Primary endpoint
25 July 2023

25 July 2023

Quick facts

Lead sponsor	University of California, Los Angeles
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	12 January 2023
Primary completion	25 July 2023
Estimated completion	25 July 2023
Sites	1 location across United States

Drugs / interventions tested

Perclose
Statseal — full drug profile →

Conditions studied

Arterial Occlusion — all drugs for Arterial Occlusion →
Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
Hematoma — all drugs for Hematoma →

Sponsor

University of California, Los Angeles

Who can join

18 and older, any sex, with Arterial Occlusion or Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Time to Hemostasis Primary · 24 hours post procedure (± 1 hour)

From the time of manual compression after PercloseTM deployed until hemostasis is achieved without complication.

Group	Value	95% CI
Perclose Only	5.11	± 4.4
Perclose With Statseal Device	4.3	± 4.4

Patients With Hematoma Secondary · 24 hours post procedure (± 1 hour)

Presence of small \<5cm, medium 5-10cm, or large \>10cm hematoma based on physical exam or diagnostic imaging.

Small <5cm

Group	Value	95% CI
Perclose Only	0
Perclose With Statseal Device	0

Medium 5-10cm

Group	Value	95% CI
Perclose Only	0
Perclose With Statseal Device	0

Large >10cm

Group	Value	95% CI
Perclose Only	1
Perclose With Statseal Device	1

Sponsor's own description

The purpose of this clinical study is to compare how well two different devices achieve hemostasis in patients undergoing a transfemoral transcatheter aortic valve replacement. Both devices are approved by the FDA for this use, and have already been used by clinicians on patients undergoing transfemoral procedures. It is believed that the use of both devices in combination compared to the Perclose alone will shorten the time that it takes to 'seal' the artery, resulting in a shorter period of time that manual pressure will be held, shorter procedure time and less complications after the procedure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Perclose

Trials testing the same drug.

NCT05468957 — Comparing Perclose to Statseal in Conjunction With Perclose in Femoral 6 French Arteriotomy Closure · NA · withdrawn

Other recruiting trials for Arterial Occlusion

Currently open trials in the same condition.

NCT06095050 — Embolization Treatment of Chronic Refractory Shoulder Tendinopathy · NA · recruiting

Other University of California, Los Angeles trials

Trials by the same sponsor.

NCT04846517 — rTMS for Aneroxia Nervosa in Youth · NA · not yet recruiting
NCT06701760 — Sodium Lactate in Severe TBI · Phase 2 · not yet recruiting
NCT04996667 — Effect of iNO in Patients With Submassive and Massive PE · Phase 2 · withdrawn
NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
NCT07534696 — Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05637970 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Los Angeles
Last refreshed: 19 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05637970.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing